Close

TESARO (TSRO) to Expand Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cance

March 27, 2017 3:46 PM EDT Send to a Friend
TESARO, Inc. (NASDAQ: TSRO) today announced a substantial expansion of its niraparib clinical development program. Following the landmark results of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login